ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Model scores of the 29,894 trials active now.

Model score 27% for any early termination, 12% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-05-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: lymphomacellcancerchemotherapyprior
  Phrases that lowered it: participantsevaluatemethotrexatedoseopen label
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 15.3% (lowers risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 1 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 708198 (lowers risk) · Drug's FDA history
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 112097 (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas NCT03255018 · started 2018 · scored riskier than 84% of active trials completed
• Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma NCT01092182 · started 2010 · scored riskier than 81% of active trials completed
• Phase III Study of Tucidinostat in Combination With R-CHOP in Patients With Newly Diagnosed Double-Expressor DLBCL NCT04231448 · started 2020 · scored riskier than 76% of active trials completed
• Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma NCT04433182 · started 2020 · scored riskier than 72% of active trials terminated
• Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP. NCT01805557 · started 2013 · scored riskier than 62% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.